MedTrace Logo

Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China

NCT03792529 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2019-01-03

No results posted yet for this study

Summary

The anticipated objectives of this study are: 1) to understand the pathogenesis and molecular typing of breast cancer patients in China (mainly HER2 overexpression, triple negative and hormone receptor-positive patients) by detecting DNA and RNA in tumor tissue (fresh tissue or paraffin section), and to compare the similarities and differences between the western population and Chinese population; 2) plasma samples of patients with HER2 overexpression , hormone receptor-positive and triple negative (ER, PR, HER2 expression negative) were sequenced for ctDNA and ctRNA, to find out whether there are genes or gene sets related to therapeutic effect; 3) to study the specific changes of liquid molecular detection results according to the previous research results, and establish mathematical models to predict and monitor the effects of targeted therapy and endocrine therapy; 4) to compare liquid biopsy and imaging and clinical features in monitoring clinical therapeutic effect, and to elaborate the advantages and disadvantages of liquid biopsy and conventional imaging; 5) to provide molecular detection basis for follow-up clinical research and screening for targets of new drugs.

Conditions

Interventions

OTHER

detect gene mutations of ctDNA and ctRNA

Samples were collected from patients at baseline, during therapy and after disease progression, and gene mutations of ctDNA and ctRNA were detected in the samples.

Sponsors & Collaborators

  • Predicine (Shanghai) Medical Technology Co., Ltd.

    collaborator UNKNOWN

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Huiping Li · Peking University Cancer Hospital & Institute

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-20
Primary Completion
2019-06-01
Completion
2019-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03792529 on ClinicalTrials.gov